Phase II study to evaluate safety and efficacy of MEDI4736 (durvalumab) plus radiotherapy in patients with newly diagnosed unmethylated MGMT glioblastoma (new unmeth GBM) Meeting Abstract
| Authors: | Reardon, D. A.; Kaley, T. J.; Dietrich, J.; Clarke, J. L.; Dunn, G.; Lim, M.; Cloughesy, T. F.; Gan, H. K.; Park, A. J.; Schwarzenberger, P.; Ricciardi, T.; Macri, M. J.; Ryan, A.; Venhaus, R. R. |
| Abstract Title: | Phase II study to evaluate safety and efficacy of MEDI4736 (durvalumab) plus radiotherapy in patients with newly diagnosed unmethylated MGMT glioblastoma (new unmeth GBM) |
| Meeting Title: | 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 37 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2019 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2019-05-20 |
| Start Page: | 94s |
| Language: | English |
| ACCESSION: | WOS:000487345804414 |
| DOI: | 10.1200/JCO.2019.37.15_suppl.2032 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 2032 -- Source: Wos |
